Cravath-Led J&J Paying $14.6B For Neuropsychiatric Drug Co.
By Al Barbarino · January 13, 2025, 1:53 PM EST
Johnson & Johnson said Monday it has agreed to purchase Intra-Cellular Therapies Inc., a biopharmaceutical company focused on therapies for neuropsychiatric and neurological disorders, for approximately $14.6 billion....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login